Qualigen, Inc., a privately owned company that provides rapid, easy to use, fully quantitative diagnostic testing solutions, announced today that its Board of Directors has elected Kurt H. Kruger to the Board, effective June 26, 2017.
Mr. Kruger has enjoyed a 30-year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Kurt worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Kurt has overseen the IPOs of over 30 medical products companies, and for the last three years he has headed up the Life Sciences banking effort for WR Hambrecht & Co.
Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University, a Master’s degree in Bioengineering from the University of Michigan and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.
“We are indeed fortunate to have Kurt Kruger join our Board. Kurt has extensive knowledge of the healthcare industry, having worked in product development and then investment banking. We are honored that Mr. Kruger has agreed to serve on the Board for Qualigen,” said Michael S. Poirier, Chairman of the Board.
